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G protein-coupled receptors (GPCRs) are involved in the pathophysiology of a wide range of
diseases and constitute an attractive therapeutic target. In the thyroid gland, TSH receptor (TSHR),
a member of the GPCR family, is a major regulator of thyroid differentiation and function.
Alterations in TSHR activity are often involved in the development of pathologies such as thyroid
cancer and thyroid enlargement (goiter). Here we show that DREAM (downstream regulatory
element antagonist modulator) modulates TSHR activity through a direct protein-protein inter-
action that promotes coupling between the receptor and Gs. In transgenic mice, DREAM over-
expression provokes a marked enlargement of the thyroid gland. Increased levels of DREAM
protein were observed in human multinodular goiters, suggesting a novel etiopathogenic mech-
anism in nodular development in humans. Taken together, these findings identify a mechanism
for the control of TSHR activity andprovide a newapproach for the study and treatment of thyroid
pathologies associated with impaired TSHR function. (Molecular Endocrinology 23: 862–870, 2009)
G protein-coupled receptors (GPCRs) are membrane pro-teins located on the cell surface from where they control
cell physiology through the activation of various signaling cas-
cades. Impaired function of specific GPCRs is strongly impli-
cated in the pathophysiology of a wide range of conditions,
including among others, pain, inflammation, obesity, hyperten-
sion, cardiovascular disease, or generalized anxiety disorder (1–
7). Because of this and their accessibility to drugs, GPCRs are
indisputably an attractive class of therapeutic targets. In the
thyroid gland, TSH is themajor regulator of thyroid growth and
differentiation. TSH binds to the TSH receptor (TSHR) and
induces coupling toG proteins (8, 9), of which heterotrimeric Gs
protein mediates most of the TSHR signaling and activates a
cAMP cascade that controls the expression of key genes in thy-
roid function (10).
TSHR is associated with many thyroid diseases (11). Inacti-
vating mutations of TSHR are responsible for asymptomatic
resistance to TSH and overt congenital hypothyroidism. Acti-
vatingmutations of TSHR are found in autonomously function-
ing thyroid nodules, thyroid hyperplasia, and congenital hyper-
thyroidism (12–15). Development of TSHR autoantibodies that
bind to and stimulate TSHR activity causes Graves’ disease,
which is one of the most prevalent human autoimmune diseases
(16, 17). Furthermore, it has been shown that TSHR maintains
a relatively high activity in the absence of TSH (18, 19), yet the
molecular mechanism and the physiological relevance for this
are unknown (20).
DREAM (downstream regulatory element antagonist mod-
ulator) is a neuronal calcium sensor preferentially expressed in
the central nervous system and the thyroid gland (21). DREAM,
also named KChIP-3 (K channel interacting protein-3), be-
longs to a group of structurally and functionally related proteins
(KChIP-1 to -4) that interact with Kv4 potassium channels to
regulate their membrane expression and gating (21–23). In the
nucleus, DREAM is a calcium-, cAMP-, and phosphatidylino-
sitol 3-kinase-sensitive transcriptional repressor that regulates
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transcription by binding to specific sites in target genes (21,
24–27) or through the interaction with other nucleoproteins
(28, 29). In neurons, DREAM represses basal expression of the
prodynorphin gene, and DREAM knockout mice display a
hypoalgesic phenotype, suggesting a critical role for DREAM
in pain modulation (30). In thyroid follicular cells, DREAM
modulates the transcriptional activity of thyroid transcrip-
tion factor-1 (TTF-1) and represses thyroglobulin (Tg) gene
expression (29).
In the present work, we show that DREAM functions as an
intracellular TSHR ligand that controls receptor protein levels
and promotes its coupling toGs protein. Analysis of transgenic
mice and human patients support an etiopathological role of
elevated levels of DREAM in human multinodular goiters.
Results
DREAM regulates thyroid growth and differentiation
DREAM regulates Tg expression in follicular cells (29). To
further investigate DREAM function in the thyroid gland, we
generated two independent lines of transgenic mice, LeuBTA7
and LeuBTA15, which express different levels of a dominant
active DREAM mutant insensitive to both calcium and
cAMP/protein kinase A (21, 25) (Fig. 1A). Histological anal-
ysis of 2- to 3-month-old mice revealed a nonnodular, diffuse,
and homogeneous hyperplasia of the gland with small follicles
lined by columnar epithelium in both transgenic lines (Fig. 1,
B–E). Quantitative RT-PCR analysis of the glands confirmed
this observation and showed an increase in the proliferation
marker proliferating cell nuclear antigen (Fig. 1F). Analysis of
thyroid glands from 9- to 12-month-old mice showed a marked
enlargement of the transgenic gland [12.4 2.1 mg (LeuBTA7)
and 13.84  1.6 mg (LeuBTA15)] compared with wild-type
(4.4 0.3 mg) that could be either diffuse, resembling a colloid
goiter, or nodular, resembling humanmultinodular goiters (Fig.
2A). In the colloid goiter phenotype, many follicles showed a
large lumen, irregular shape, colloid accumulation, and low
cuboidal or flattened epithelium, which is a sign of hypoactivity
(Fig. 2, compare B and EwithC and F).Heterogeneity prevailed,
and the glands showed also hyperplastic areas with follicles
surrounded by a tall, active epithelium forming papillary infold-
ings protruding into the lumen (Fig. 2, D and G) or with small
follicles lined with a tall epithelium resembling follicular adeno-
mas (Fig. 2H), nodules (Fig. 2I), and highly hyperproliferative
foci without follicular structure. Nodularity is the typical evo-
lution of colloid goiters andwas observed also in oldmice. Some
heterogeneity, however, was found between animals and within
each thyroid gland, which is a common finding in thyroid pa-
thologies and agrees with the variable phenotypes of the thyroid
in response to the same stimulus (15, 31).
Analysis of several differentiation markers in 2- to 3-month-
old mice showed a significant down-regulation of Tg mRNA
and up-regulation of genes involved in thyroid hormone synthe-
sis, such as the sodium-iodide symporter (NIS), and thyroid
peroxidase (TPO) (Fig. 3). Similar results, although less pro-
nounced, were observed in older mice (Fig. 3).
As a result, the euthyroid state was maintained and no sig-
nificant changes in T3, T4, and TSH serum levels were observed
at any age in DREAM transgenic mice (supplemental Fig. 1,
published as supplemental data on The Endocrine Society’s
Journals Online web site at http://mend.endojournals.org).
Increased cAMP signaling in the thyroid gland of
DREAM transgenic mice
To investigate the mechanism underlying the observed phe-
notype, we focused on modifications in the cAMP cascade,
which is known to be involved in the pathogenesis of several
thyroid diseases. We found that transgenic thyroid glands con-
tained significantly higher levels of TSHR and cAMP than wild-
type glands (Fig. 4, A and B). As a consequence, levels of phos-
phorylated cAMP response element-binding protein (CREB)
were also increased in transgenic glands, without change in total
CREB protein (Fig. 4B and supplemental Fig. 2). Noteworthy,
increased TSHR protein did not correlate with increased
TSHR mRNA (supplemental Fig. 3), indicating that the in-
crease in TSHR levels is not due to transcriptional activation
of the TSHR gene.
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FIG. 1. Early morphological and proliferative changes in young transgenic mice.
A, Quantitative real-time PCR showing HPRT mRNA-normalized expression levels
(mean  SEM) of endogenous (white bars) and mutant DREAM (black bars) in the
thyroid of 2- to 3-month-old wild-type (wt) and LeuBTA7 and LeuBTA15 DREAM
transgenic mice. B–E, Hematoxylin and eosin staining of paraffin sections from 2-
to 3-month-old wild-type (B–D) and transgenic (C–E) mice. A representative
example of the hyperproliferative phenotype observed in both transgenic lines is
shown. Magnification, 100 (B and C) and 600 (D and E). F, Quantitative real-
time PCR showing HPRT mRNA-normalized expression level (mean  SEM) of
proliferating cell nuclear antigen in wild-type (n  9), LeuBTA7 (n  8), and
LeuBTA15 (n  11) mice. Significant differences from wild-type mice by unpaired
Student’s t test are indicated: *, P  0.0252; **, P  0.0027.
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To analyze the relation between DREAM overexpression
and increased TSHR/cAMP signaling, we generated stable
clones of thyroid PC Cl3 cells that overexpress wild-type
DREAM, mutant DREAM insensitive to calcium (EF-
mDREAM), or mutant DREAM insensitive to cAMP (Leu-
mDREAM) (21, 28). These mutations correspond to those
expressed simultaneously in DREAM transgenic mice. Unex-
pectedly, overexpression of wild-type DREAM induced an
increase in intracellular TSHR, cAMP, and phospho-CREB
similar to that observed with either DREAM mutant (supple-
mental Fig. 3, B–D). These results indicate that overexpres-
sion of DREAM protein, regardless of whether it is mutated
or not, is responsible for the induction of the cAMP cascade
observed in transgenic mice. The fact that DREAMmutations
are not needed for TSHR/cAMP activation suggests a role for
endogenous DREAM in tonic activation of TSHR in basal
conditions.
DREAM-induced activation of the
cAMP signaling pathway is mediated
by TSHR
To link the effect of DREAM on cAMP
signaling to TSHR, we transfected DREAM
into TSHR-10,000 cells, a CHO-derived
cell line, that stably overexpress TSHR (19)
or into the original CHO-K1 cells. In basal
conditions, TSHR-10,000 cells contain
higher levels of cAMP and phospho-CREB
(Fig. 4, C andD) than CHO-K1 cells due to
the constitutive activity of TSHR in the ab-
sence of TSH (19). Expression of DREAM
resulted in a significant increase in cAMPand
phospho-CREB levels in TSHR-10,000 cells
and no changes in CHO-K1 cells (Fig. 4,
C andD). The effects of DREAMon TSHR
and cAMP signaling were not reproduced
by expression of KChIP-2 (Fig. 4C and sup-
plemental Fig. 4), a closely related member
of the DREAM/KChIP family that is ex-
pressed in the thyroid gland (29). These
data indicate that activation of cAMP sig-
naling is specific of DREAM and is medi-
ated by TSHR.
DREAM interacts with TSHR
DREAM has been reported to interact
with proteins in the nucleus and in the cy-
toplasm (32). Therefore, we next investi-
gated whether DREAM is able to interact
with TSHR. Using thyroid glands from
wild-type and transgenic mice, we show
that TSHR coimmunoprecipitates with
DREAM (Fig. 5A). The interaction was
confirmed using cell extracts from TSHR-
10,000 cells transfected with DREAM-
hemaglutinin (HA) (Fig. 5B).
To further characterize the interaction
between DREAM and TSHR, we used
Myc-tagged TSHR fragments (Fig. 5C) transfected together
with DREAM-HA in CHO-K1 cells. Immunoprecipitation
showed that DREAM specifically interacts with the C-terminal
(Ct) intracellular region of TSHR (Fig. 5D). Conversely, exper-
iments using Myc-tagged DREAM fragments (Fig. 6A) revealed
that the N-terminal (Nt) region of DREAM containing the first
90 amino acids (DREAM1-90) is needed for the interaction
with the receptor (Fig. 6B). Coimmunoprecipitation experi-
ments using TSHR Ct-Myc and DREAM1-90-HA constructs
confirmed that the Ct region (amino acids 696-763) of the re-
ceptor is able to interact directly with the 1-90 fragment of
DREAM (Fig. 6C).
DREAM-derived peptides activate cAMP signaling
Previous work by others has shown that calreticulin interacts
with and stabilizes TSHR (33). Overexpression of calreticulin in
TSHR-10,000 cells, however, did not increase cAMP levels
FIG. 2. Thyroid histopathology in 9- to 12-month-old mice. A, Gross appearance of thyroid glands
from wild-type (left) and transgenic mice with diffuse goiter (middle) or multinodular goiter (right). B–J,
Hematoxylin and eosin staining of paraffin sections from wild-type (B and E) and transgenic (C, D, F–J)
mice. C and F, Transgenic glands showing follicles with large lumens surrounded by flat epithelium. D
and G, Hyperplastic areas with follicles surrounded by tall epithelium forming papillary infoldings
protruding into the lumen. H, Adenomatous hyperproliferation (asterisk). Nodules with disorganized
follicular structure (I) and nonfollicular hyperproliferative foci (arrowhead in J). Similar heterogeneity
and pathological phenotypes were observed in both transgenic line LeuBTA7 (D, G, H, and J)
and LeuBTA15 (A, C, F, and I). Magnification, 50 (B–D), 1000 (E and F), 400 (G), and 200 (H,
I, and J).
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(supplemental Fig. 5), indicating that receptor stabilization and
increased cAMP signaling are independent events. To further
investigate the molecular basis for this effect, we checked
whether DREAM fragments can directly activate the receptor as
intracellular agonists. Expression in TSHR-10,000 cells showed
that amino acids 43–90 of DREAM are involved in the activa-
tion of TSHR (Fig. 7A). To narrow down the residues directly
responsible, we analyzed the effect of three overlapping pep-
tides, P1, P2, and P3, that cover this region (Fig. 7A). Exposure
of TSHR-10,000 cells to P1 specifically activated the cAMP
cascade and increased phospho-CREB levels without increasing
TSHR protein levels (Fig. 7, B and C). Similar results were ob-
served in PC Cl3 thyroid cells (data not shown). P1 also in-
creased cAMP levels in the human ML-1 line of poorly differ-
entiated thyroid carcinoma cells (Fig. 7D) that contain low
levels of TSHR (34) but not in NPA cells (Fig. 7E), a cell line
originally described as papillary thyroid cancer (35), which does
not express detectable levels of THSR (36). Using TSHR-10,000
cells, coimmunoprecipitation showed that both DREAM and
P1, like TSH (10), enhanced the coupling between TSHR and
Gs (Fig. 7F). These data indicate that the P1 peptide, which
neither stabilizes nor increases TSHR levels is still able to induce
the cAMP cascade, strongly supporting DREAM as an intracel-
lular TSHR ligand.
Endogenous DREAM regulates TSHR activity
To further substantiate a physiological role of endogenous
DREAM in TSHR function, we transiently knocked down
DREAM expression in PC Cl3 thyroid cells using a previously
characterized antisense vector (37). Reduction by
50–60% of the endogenous DREAM levels re-
sulted in decreased TSHR, cAMP, and phospho-
CREB levels, without change in total CREB (Fig.
8, A and B). This effect was specific for DREAM
knock-down because it was not observed using an
antisense vector for KChIP-2, in keeping with the
lack of effect of KChIP-2 on the receptor (see Fig.
4C and supplemental Fig. 4). Analysis of thyroid
glands from DREAM knockout mice (30) con-
firmed the antisense knock-down data and
showed reduced levels of TSHR and cAMP (Fig.
8, C and D). Consistently, thyroid glands from
DREAM knockout mice showed unstructured
follicular pattern and cellular hypoactivity (sup-
plemental Fig. 7). Complete characterization of
the thyroidal phenotype in DREAM knockout
mice is currently under investigation (Zannini,
M. S., personal communication). Taken together,
these data support a physiological role for endog-
enous DREAM in the control of TSHR activity in
thyroid cells.
Analysis of DREAM and TSHR in human
multinodular goiters
To investigate the pathophysiological relevance
of the DREAM-TSHR interaction, we carried out
Western blot analysis of nodules from human
multinodular goiters using the surrounding normal
tissue as control (Fig. 9). We found a higher than
2-fold increase in DREAMprotein levels in nodular
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samples in 10 of 16 multinodular goiters. Representative exam-
ples (patients 1, 2, 4, 6, 7, and 8) are shown in Fig. 9A (for
complete patient data set, see supplemental Table 1). Changes in
DREAM levels were paralleled by TSHR, and statistical analysis
showed a positive correlation between DREAM and TSHR pro-
teins, supporting the notion that DREAM is able to modulate
TSHR levels in the human thyroid gland (Fig. 9A). The increase
in TSHR protein was not associated with an increase in TSHR
mRNA (data not shown). A positive correlation was also ob-
served between DREAM and phospho-CREB, suggesting that
DREAM affects the cAMP signaling pathway. By contrast, a
negative correlation was found between DREAM and Tg (Fig.
9C), which agrees with the transcriptional repression of the Tg
promoter by DREAM in vitro (29) and in transgenic mice
(see Fig. 3). No statistically significant correlations between
DREAMandERK-2,-actin, andCREBwere found in the same
samples (Fig. 9A and data not shown). Together, these data
suggest that up-regulation of endogenous DREAM may con-
tribute to the development of thyroid nodules.
Discussion
Binding of TSH to its receptor controls thyroid function mainly
through activation of the cAMP signaling pathway (10, 38, 39).
Changes in TSHR activity due to point mutations or in response
to auto-antibodies modify the cAMP cascade and have clinical
consequences (11). In addition, TSHR displays a relatively high
basal activity in the absence of TSH. The physiological signifi-
cance and the existence of endogenous mediators of such spon-
taneous activity are not well understood (18, 19). In the present
work, we show that DREAM is an endogenous intracellular
effector of TSHR function that activates cAMP signaling.
DREAM transgenic thyroid glands showed increased cAMP
and phospho-CREB levels, induction of the cAMP-regulated
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genes NIS and TPO, hyperproliferation, and goiter development.
DREAM transgenic mice, however, do not show significant
changes in T3, T4, or TSH levels as described in other models in
which cAMP is constitutively activated (40).Maintenance of the
euthyroid state could be related to the repression of Tg observed
in DREAM transgenic glands (29), although the exact mecha-
nism has not been established.
Calcium-binding proteins of the neuronal calcium sensor su-
perfamily have been shown to regulate the activity of several
cytosolic and membrane proteins. Thus, visinin-like protein-1
modulates the activity of guanylyl cyclase B aswell as the surface
expression and sensitivity for agonists of nicotinic receptors (22,
41–43). Ca-binding protein 4 regulates calcium influx in pho-
toreceptor synaptic terminals through its interaction with the
Cav1.4 channel (44). Likewise, DREAM has been associated
with trafficking of Kv4 potassium channels to the plasma mem-
brane and regulation of channel gating (22, 45), and like visinin-
like protein-1 and other neuronal calcium sensor family mem-
bers (46), DREAM regulates the membrane binding and kinase
activity of G protein-coupled receptor kinase (47). The effect of
DREAM on TSHR activity is specific and is mediated through
the Nt TSHR-interacting region of DREAM. This domain is not
present in KChIP2, otherwise a highly conserved member of the
DREAM/KChIP family. Thus, KChIP2 does not regulate TSHR
activity, and its expression in the thyroid gland could be related
to transcriptional control in combination with DREAM (29).
Previous work has shown that, like DREAM, calreticulin inter-
acts and stabilizes TSHR. Calreticulin, however, did not induce
the cAMP cascade, indicating that protein stabilization is not
enough to explain the TSHR activation elicited by DREAM.
Likewise, the DREAM-derived P1 peptide directly activates
TSHR, promotes its coupling to Gs and increases cAMP levels
without stabilizing the receptor. Therefore, the activation elic-
ited by DREAM is an independent effect not related to TSHR
levels.
TSHR signaling is modulated by a number of posttranslational
modifications, including phosphorylation by GRKs and Nt glyco-
sylation (48, 49) changes that determine receptor desensitization
and proper folding and membrane expression, respectively. In ad-
dition, TSHR function is regulated by oligomerization (50) and
interaction with the membrane-associated PDZ protein hScrib
(51),whichdetermine intracellular trafficking andpromotes recep-
tor recycling blocking endocytosis, respectively.WhetherDREAM
interferes at these levels is presently unknown, but a Ca2-depen-
dent interaction between DREAM and the PDZ-containing pro-
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tein PSD-95 has been observed in neurons (Naranjo, J. R., unpub-
lished observations).
Our results show that DREAM interacts with the Ct cytosolic
domain of TSHR. This region shares an approximately 70% ho-
mology with the Ct region of other glycoprotein-hormone recep-
tors such as the FSH receptor and LH/chorionic gonadotropin
receptor (10). Low molecular weight agonists or antagonists for
these receptors have the potential to become oral therapeutics for
infertility or contraception treatment, respectively (52).These stud-
ies have given rise to the discovery of molecules that bind to the
TSHR transmembrane region and display partial agonist or antag-
onist activity although toomoderate to be clinically useful (52, 53).
Further experiments will be required to investigate the therapeutic
value of DREAM and DREAM-derived peptides in pathologies
associated with impaired TSHR, FSH receptor, or LH/chorionic
gonadotropin receptor function. Activation or blockade ofGPCRs
by cell-penetrating peptides has been previously described (54) and
was found to be of potential therapeutic value (55, 56). Theses
peptides (named pepducins) derive from the intracellular trans-
membrane loopsofGPCRsand, likeDREAM, require theCtof the
receptor to activate G proteins.
Taken together, our data from cultured follicular cell lines, thy-
roid glands from transgenicmice, and humanmultinodular goiters
reveal a newmolecularmechanism that links deregulatedDREAM
expression with thyroid enlargement and nodular development.
Materials and Methods
Plasmids
Plasmids for wild-type DREAM, DREAM mutants, and expression
vectors for antisenseDREAMandKChIP-2 have beenpreviously described
(25, 37). TSHR and DREAM deletion fragments
were cloned in the pCS2Myc expression vector us-
ing the ClaI and the NcoI-XhoI sites, respectively.
Calreticulin cDNA (a gift from Dr. M. Michalak,
Canada) was subcloned in a pcDNA3-HA vector.
Sequences of PCR primers for the DREAM and
TSHR fragments are given in supplemental informa-
tion. The plasmids were verified by sequencing on
both strands.
Animals
The proximal bovine Tg promoter (40, 57) was
used to target the dominant active DREAM mutant
insensitive to calcium and cAMP (LeuEFmDREAM)
to the thyroid gland. The transgenic cassette was mi-
croinjected into the pronuclei of one-cell embryos
(C57BL/6  CBA F1) using standard techniques.
Transgenic progeny were identified by qualitative
PCR of tail DNA using specific primers (supplemen-
tal information). Foundermales were backcrossed to
C57BL/6 females to generate lines that were main-
tained as heterozygotes. DREAM knockout mice
(30)werekindlyprovidedby J.M.Penninger. Female
mice were analyzed in all experiments using wild-
type littermates as controls. Experiments were ap-
proved and conducted according to institutional re-
view board guidelines.
Cells
CHO-K1 cells stably transfected with human
TSHR (TSHR-10,000 cells) (19) and the original CHO-K1 cell line were
kindly provided byDr. B. Rapoport. The cells weremaintained inHam’s
F12 medium supplemented with Glutamax, fetal bovine serum (5%),
and penicillin/streptomycin. Rat thyroid follicular PC Cl3 cells were
cultured in DMEM/F12 (1:1) medium with Glutamax and supple-
mentedwith 5%calf serum and a six-growth-factor complement includ-
ing TSH (0.5 mU/ml), insulin (10 g/ml), somatostatin (10 ng/ml), hy-
drocortisone (10 nM), transferrin (5 g/ml), and glycyl-histidyl-lysine
(10 ng/ml). When cells were incubated in the absence of TSH, the calf
serum concentration was reduced to 0.2%. Transfections were carried
out with the JetPEI transfection reagent. For stable transfection, PC Cl3
cells received 5 g plasmid DNA expressing either wild-type DREAM,
EFmDREAM, EFLmDREAM, or empty pcDNA3 vector. Cells were
selected after 3 wk with 300 g/ml G418. ML1 and NPA cell lines,
kindly provided by Dr. K. To¨rnquist, were cultured as described (58).
Peptide delivery
Peptides were delivered using the PULSin protein delivery reagent
(Polyplus transfection) using the manufacturer’s protocol. For cAMP as-
says, peptides were added to 12-well plates (final concentration 2M), and
for Western blots, peptides were added to 35-mm dishes (final concentra-
tion 2 or 3 M). Peptide penetration into cells was analyzed by immuno-
fluorescence using rhodamine-labeled peptides and showed thatmore than
90% of cells incorporated the peptide after 4 h incubation (not shown).
Therefore, cells were analyzed after 4 h incubation with peptides.
cAMP assay
cAMP concentration in cells and thyroid gland extracts was mea-
sured using the Biotrak enzyme immunoassay system (GE Healthcare,
Piscataway, NJ). Cells were plated in 12-well plates (1.7  105 PC Cl3
cells or 1.25 105 TSHR-10,000 cells per dish) and collected after 24 h
(PCCl3 stable clones) or 24 h after transient transfection (TSHR-10,000
cells). Proliferation profiles were not significantly different among con-
trol and DREAM-transfected cultures, and therefore cAMP values were
normalized per well. In the experiments with DREAM-derived peptide,
cells were collected after 4 h incubation with the peptide.
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Histology
Thyroid glands were fixed in 4% paraformaldehyde in PBS over-
night at 4 C, dehydrated through ethanol series, cleared in xylene, em-
bedded in paraffin, and sectioned at 5 m. For histological examina-
tions, serial sections from transgenic and wild-type mice were stained
with Harry’s hematoxylin and eosin.
Quantitative real-time RT-PCR
Total RNA from thyroid glands was prepared using Trizol. After
reverse transcription, quantitative PCR was performed using specific
primers and TaqMan probes. The sequences of primers and probes are
given in supplemental information.
Coimmunoprecipitation and Western blot
For coimmunoprecipitation experiments, whole-cell extracts were
prepared from thyroid glands, PC Cl3 cells, or transfected cells by in-
cubation in Nonidet P-40 (NP40) lysis buffer [50 mMTris (pH 8.0), 150
mM NaCl, 1% NP40, and protease inhibitor cocktail]. Extracts were
precleared with protein G-Sepharose for 1 h and incubated overnight at
4 C with a monoclonal antibody against DREAM (28) or with anti-HA
(sc-7392; Santa Cruz Biotechnology, Santa Cruz, CA). Immune com-
plexes were captured for 2 h with protein G-Sepharose in lysis buffer
containing 5% BSA, and beads were washed three times in lysis buffer.
The same protocol using protein A-Sepharose was used for immunopre-
cipitation of TSHR andMyc-fusion proteins with goat and rabbit poly-
clonal antibodies, respectively. Protein complexes were eluted with SDS
sample buffer and analyzed by immunoblot. For membrane protein
preparations cells were lysed in buffer [20 mM Tris (pH 7.5), 0.32 M
sucrose, 0.2 mM EDTA, and 0.5 mM EGTA and protease inhibitor
cocktail]. After sonication, cells were centrifuged at 50,000 rpm and
pellets resuspended in GTED buffer [20% glycerol, 10 mM Tris (pH
7.5), 1 mM EDTA, and 1 mM dithiothreitol]. Cell extracts were resolved
in SDS-PAGE and transferred to polyvinylidene difluoride membranes.
Rabbit polyclonal anti-DREAM has been described (37). The poly-
clonal antibody for TSHR (sc-7816; Santa Cruz) is directed against the
N-terminal region and recognizes the full-length and theA subunit of the
receptor. Antibodies against ERK-2 (sc-153), Gs (sc-823), and c-Src
(sc-19) were from Santa Cruz; phospho-CREB (9191S) and total CREB
(9192) from Cell Signaling (Beverly, MA); Myc (ab9106-100) from
Abcam (Cambridge, MA); and -actin (A-5441) from Sigma Chemical
Co. (St. Louis, MO). Blots were developed by enhanced chemilumines-
cence and quantified using the NIH Image software.
Human sample analysis
Human samples were obtained after informed consent and formally
approved by the Ethical Committee at the Federico II University in Naples,
Italy. All clinical investigation has been conducted according to the princi-
ples expressed in the Declaration of Helsinki. After surgical removal, sam-
ples were immediately frozen in liquid nitrogen. Samples were lysed in
NP40 lysis buffer and analyzed by Western blot as indicated above.
Statistics
The correlation analysis and Student’s t test applied for two group
comparisons were done using the Prism statistical software. Values with
P  0.05 were considered significant. For cAMP assays, the number of
independent experimentswere at least three (n3) carried out in triplicate.
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